Medical device maker Stryker disclosed last month that federal authorities—for the third time in a decade—are investigating whether the company broke a federal anti-bribery law.

The Department of Justice and Securities and Exchange Commission inquiry is a stark reminder that even as compliance teams struggle to keep up with new regulations, including state privacy and pay-transparency laws, the decades-old Foreign Corrupt Practices Act still looms as a colossal risk for multinational companies.